Curated News
By: NewsRamp Editorial Staff
June 03, 2024
Candel Therapeutics Reports Positive Phase 2 Trial Data for CAN-2409 in Pancreatic Cancer
TLDR
- Candel Therapeutics, Inc. reported significant improvement in overall survival in pancreatic cancer patients with CAN-2409 treatment.
- CAN-2409, an off-the-shelf adenovirus, elicits a systemic immune response in pancreatic cancer patients, leading to improved survival rates.
- CAN-2409 treatment shows promise in extending the survival of pancreatic cancer patients, offering hope for more effective treatment options in the future.
- The updated data from Candel Therapeutics' clinical trial demonstrates the potential of CAN-2409 to induce a robust antitumoral immune response in pancreatic cancer.
Impact - Why it Matters
The release of updated survival data from Candel Therapeutics' phase 2 clinical trial of CAN-2409 in pancreatic cancer is significant as it demonstrates promising results in improving overall survival for patients with borderline resectable pancreatic cancer. This could potentially lead to a new treatment option for a disease that accounts for approximately 3% of all cancers in the U.S., impacting thousands of patients each year.
Summary
Candel Therapeutics, Inc. (NASDAQ: CADL) released updated survival data from its phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. The trial indicated very promising results, with patients experiencing a median overall survival of 28.8 months after treatment with CAN-2409, compared to 12.5 months in the control group. No new safety signals were observed, and the therapy was generally well tolerated. The company's lead product candidate, CAN-2409, is an off-the-shelf viral immunotherapy designed to induce a systemic immune response against tumors.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Candel Therapeutics Reports Positive Phase 2 Trial Data for CAN-2409 in Pancreatic Cancer
